[The concept of the nontraditional use of histochemical stains].
A priority concept is produced, according to which stains, which have traditionally been used in pathological anatomy for structural and morphological studies of changes occurring in the cell during pathology, and also for postmortem diagnosis, are suggested for use as medicines. This nontraditional use of strains is based on the results of pathohistologic studies and is regarded as a new pharmacotherapeutic strategy--"address histochemical pharmacotherapy" or "pharmacotopographic therapy". Its main principle is "stopping by staining," i.e., the inhibition of a pathological process by the staining of "address substrates", i.e., the biochemical ingredients of the cell involved in a given pathology. Stain blocking of the "address substrates" of the cells in which pathology originates and develops excludes them from the pathogenetic chain of the disease. Staining biochemically "switches over" the pathology onto the path of normalization and thus softens the course of the disease. "Address histochemical pharmacotherapy" implies the direct effect of the dye on the pathology (the medicating function of the dye) and the delivery of the necessary medicating enzymes, activators, or enzyme inhibitors together with the dye to the site of pathology (the transport function of the dye). A scheme for biological trials of the stains as potential means of "address histochemical pharmacotherapy" is given. The data in the literature on the pathohistology of some diseases is analyzed and various types of pathology control by histochemical stains is suggested.
Piruzian
L A
LA
Mikhaĭlovskiĭ
E M
EM
D000818:Animals; D002986:Clinical Trials as Topic; D004396:Coloring Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004358:Drug Therapy / Q000379:methods; D006651:Histocytochemistry; D006801:Humans; D013194:Staining and Labeling
D004396:Coloring Agents